Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Anebulo Pharmaceuticals Inc. Common Stock
ANEB | US
1.86
USD-0.10
-5.17%
ANEB | US
About Anebulo Pharmaceuticals Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.86
Open
1.85
High
1.93
Low
1.85
Anebulo Pharmaceuticals Inc. a clinical-stage biotechnology company engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001 a small molecule cannabinoid receptor antagonist which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway Texas.
View LessANEB | US
Risk
120.5
Sharpe
-0.28
Luna's Score
36/100
Recommendation
Sell
Luna says (ANEB | US)
What's Working
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
59.6%1 month
120.5%3 months
146.2%6 months
130.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
12.45
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-6.54
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
48.24M
MarketCap(USD)
48.24M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-113.80
Short ratio
0.94
Short perc.
0.37
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.18
Range1M
1.20
Range3M
1.36
Volumes: Market Activity
Rel. volume
0.06
Price X volume
1.47K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -6.54 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 12.45 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 146.20 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 48.24M | 3.66B | Emerging |
